[1] JUNGBAUER C.Routine use of DNA testing for red cell antigens in blood centres[J].Transfus Apher Sci,2011,45(1):61-68. [2] BAKHSHANDEH Z,AMIRIZADEH N,MAGHSOODLU M,et al.Developing a databank for multiple transfusion patients:Rh antigen and phenotype distribution among 3000 regular blood donors in Iran[J].Transfus Apher Sci,2021,60(3):103124. [3] 倪修文,陈涛,罗振,等.Rh血型系统5种分型抗原同型输血在血液病患者精准化输血治疗中的价值研究[J].中国卫生检验杂志,2023,33(14):1706-1709. [4] WOREL N.ABO-mismatched allogeneic hematopoietic stem cell transplantation[J].Transfus Med Hemother,2016,43(1):3-12. [5] XU L P,LU P H,WU D P,et al.Hematopoietic stem cell transplantation activity in China 2019:a report from the Chinese Blood and Marrow Transplantation Registry Group[J].Bone Marrow Transplant,2021,56(12):2940-2947. [6] CHEN Y,WAN X J,CAO Y,et al.ABO incompatibility does not affect transfusion requirements or clinical outcomes of unrelated cord blood transplantation after myeloablative conditioning for haematological malignancies[J].Blood Transfus,2022,20(2):156-167. [7] CARRERAS E, DUFOUR C, MOHTY M, et al.The EBM T Handbook:Hematopoietic Stem Cell Transplantation and Cellular Therapies[M].Cham:Springer International Publishing,2019. [8] SHIINA T,HOSOMICHI K,INOKO H,et al.The HLA genomic loci map:expression,interaction,diversity and disease[J].J Hum Genet,2009,54(1):15-39. [9] ABOi-HSCT血型检测与血液成分输注专家共识编写组.ABO血型不合异基因造血干细胞移植受者血型检测与血液成分输注专家共识[J].中国输血杂志,2023,36(11):971-977. [10] LUTEN M,ROERDINKHOLDER-STOELWINDER B,SCHAAP N P M,et al.Survival of red blood cells after transfusion:a comparison between red cells concentrates of different storage periods[J].Transfusion,2008,48(7):1478-1485. [11] SOLVES P,CARPIO N,CARRETERO C,et al.ABO incompatibility does not influence transfusion requirements in patients undergoing single-unit umbilical cord blood transplantation[J].Bone Marrow Transplant,2017,52(3):394-399. [12] KLUMPP T R,HERMAN J H,ULICNY J,et al.Lack of effect of donor-recipient ABO mismatching on outcome following allogeneic hematopoietic stem cell transplantation[J].Bone Marrow Transplant,2006,38(9):615-620. [13] 异基因造血干细胞移植临床输血专家共识起草专家组.异基因造血干细胞移植临床输血专家共识[J].临床输血与检验,2023,25(5):586-593. [14] 于天华,遇红梅,梁海英,等.5050名患者Rh分型及不规则抗体鉴定结果分析[J].中国输血杂志,2012,25(8):756-758. [15] BACIGALUPO A.How I treat acquired aplastic anemia[J].Blood,2017,129(11):1428-1436. [16] GYURKOCZA B,SANDMAIER B M.Conditioning regimens for hematopoietic cell transplantation:one size does not fit all[J].Blood,2014,124(3):344-353. [17] 许金华,李晓丰.ABO血型不合异基因造血干细胞移植后血型转换期的输血策略[J].中国组织工程研究,2015,19(6):913-917. [18] TIWARI A K,SETYA D,AGGARWAL G,et al.Evaluation of new indigenous “point-of-care” ABO and Rh grouping device[J].J Lab Physicians,2018,10(1):80-84. [19] 魏亚明,吕毅.基础输血学[M].北京: 人民卫生出版社,2011. [20] 权军辉,张明刚,邵香,等.西安地区供受血者红细胞Rh表型匹配输注及追踪分析[J].临床输血与检验,2021,23(3):310-314. [21] WESTHOFF C M.Blood group genotyping[J].Blood,2019,133(17):1814-1820. |